Published in AIDS Weekly, April 11th, 2005
According to a study from France, "The protease inhibitor lopinavir (LPV-, [1S-[1R*(R*), 3R*,4R* -N-[4-(2,6-dimethylphenoxy)-acetyl]amino]-3-hydroxy5-phenyl-1-(phenylmethyl) pentyl] tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimide acetamide) is widely used in antihuman immunodeficiency virus (HIV) therapy.
"Knowledge of the plasma and intracellular concentrations of the drug would be useful for a better understanding of LPV action and for therapeutic monitoring. The aim of this study was to develop a sensitive and specific immunoassay for LPV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.